Your browser doesn't support javascript.
loading
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Catenacci, D V T; Kang, Y-K; Yoon, H H; Shim, B Y; Kim, S T; Oh, D-Y; Spira, A I; Ulahannan, S V; Avery, E J; Boland, P M; Chao, J; Chung, H C; Gardner, F; Klempner, S J; Lee, K-W; Oh, S C; Peguero, J; Sonbol, M B; Shen, L; Moehler, M; Sun, J; Li, D; Rosales, M K; Park, H.
Afiliação
  • Catenacci DVT; Department of Medicine, The University of Chicago Medical Centre, Chicago, USA. Electronic address: DocCatenacci@catenacciconsulting.com.
  • Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Yoon HH; Division of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, USA.
  • Shim BY; Medical Oncology, The Catholic University of Korea St. Vincent's Hospital, Suwon, Republic of Korea.
  • Kim ST; Hematology and Oncology, Samsung Medical Center, Seoul, Republic of Korea.
  • Oh DY; Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
  • Spira AI; Virginia Cancer Specialists Research Institute, Fairfax, USA.
  • Ulahannan SV; University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, USA.
  • Avery EJ; Division of Hematology and Oncology, Nebraska Hematology-Oncology, Lincoln, USA.
  • Boland PM; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA.
  • Chao J; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA.
  • Chung HC; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Gardner F; Medical Oncology, Florida Cancer Specialists, Cape Coral, USA.
  • Klempner SJ; Mass General Hospital Cancer Center, Massachusetts General Hospital, Boston, USA.
  • Lee KW; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam.
  • Oh SC; Oncology, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Peguero J; Medical Oncology, Oncology Consultants, Houston, USA.
  • Sonbol MB; Internal Medicine Department, Mayo Clinic Cancer Center, Phoenix, USA.
  • Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
  • Moehler M; Johannes-Gutenberg University, Mainz, Germany.
  • Sun J; MacroGenics, Inc., Rockville, USA.
  • Li D; MacroGenics, Inc., Rockville, USA.
  • Rosales MK; MacroGenics, Inc., Rockville, USA.
  • Park H; Department of Medicine, Washington University School of Medicine, St. Louis, USA.
ESMO Open ; 7(5): 100563, 2022 10.
Article em En | MEDLINE | ID: mdl-36029651
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article